Zacks Research Forecasts Reduced Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Zimmer Biomet in a research report issued on Wednesday, June 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $1.97 per share for the quarter, down from their previous forecast of $1.98. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's FY2025 earnings at $7.91 EPS, FY2026 earnings at $8.05 EPS and FY2027 earnings at $8.59 EPS.

Other analysts have also recently issued reports about the company. Robert W. Baird decreased their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. JMP Securities decreased their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley decreased their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Stock Down 0.3%

Shares of ZBH traded down $0.23 during mid-day trading on Friday, reaching $91.23. The company's stock had a trading volume of 1,245,408 shares, compared to its average volume of 1,811,490. The stock has a market cap of $18.05 billion, a PE ratio of 20.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.72. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet has a 12-month low of $89.22 and a 12-month high of $116.71. The company's 50 day moving average is $94.54 and its 200 day moving average is $102.09.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the prior year, the business earned $1.94 EPS. Zimmer Biomet's revenue was up 1.1% on a year-over-year basis.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds have recently bought and sold shares of the company. AG2R LA Mondiale Gestion D Actifs purchased a new position in Zimmer Biomet in the 1st quarter valued at approximately $1,179,000. Strs Ohio purchased a new position in Zimmer Biomet in the 1st quarter valued at approximately $35,652,000. Mattson Financial Services LLC increased its stake in Zimmer Biomet by 9.0% in the 1st quarter. Mattson Financial Services LLC now owns 19,636 shares of the medical equipment provider's stock valued at $2,222,000 after purchasing an additional 1,616 shares in the last quarter. Focus Partners Wealth increased its stake in Zimmer Biomet by 2.6% in the 1st quarter. Focus Partners Wealth now owns 16,955 shares of the medical equipment provider's stock valued at $1,919,000 after purchasing an additional 427 shares in the last quarter. Finally, Flaharty Asset Management LLC purchased a new position in Zimmer Biomet in the 1st quarter valued at approximately $94,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.